Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European […]
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from […]
(Michael Midmer & Dr. Mladen Vranic) Dr. Mladen Vranic, a leading scientist and advocate for the advancement of diabetes research, and teacher of innumerable renowned scientists and academic leaders, helped millions of diabetic patients all over the world with his remarkable work before he passed away on June 18, 2019. Born in Croatia in 1930, […]
TORONTO, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, is pleased to appoint Dr. Claude Piché as the Chair of its Board of Directors, replacing Luc Mainville, who has retired from the Board. Additionally, Michael […]
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, is pleased to announce that Susan Peers, PhD, has joined the organization as Director of Clinical and Regulatory Affairs. Dr. Peers is a life sciences executive with drug […]
Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep. Current therapies offer hypoglycemic treatment only once an episode occurs. Zucara is working on the first treatment to prevent hypoglycemia which can kill patients in their sleep. Vancouver, Canada: On World Diabetes Day, Zucara Therapeutics is raising awareness […]
Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust. As part of the agreement, Helmsley will provide the funding to support preclinical advancement of […]
VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) […]
Michael Midmer, CEO of Zucara Therapeutics, is confirmed to present at the 10th Annual Biotech Showcase. This important investor and networking conference is a great opportunity for Zucara to showcase our novel once-daily therapeutic to prevent hypoglycemia (low blood sugar) to life science investors and strategic partners during the industry’s most important annual gathering. More […]
NEW YORK, USA and TORONTO, Canada, September 21, 2017 — As Global Biotech Week begins in more than 20 countries, JDRF, the leading organization funding type 1 diabetes (T1D) research, is pleased to announce that it will contribute funding to Canada’s Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel therapeutic approach to […]